Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
ABCG2	9429	CHLORPROMAZINE	CHEMBL71		NCI	18834354
ABCG2	9429	PRASTERONE	CHEMBL90593		NCI	15448171
ABCG2	9429	GENISTEIN	CHEMBL44		NCI	15290869
ABCG2	9429	TACROLIMUS	CHEMBL269732		NCI	17031644
ABCG2	9429	FLUOROURACIL	CHEMBL185		PharmGKB
ABCG2	9429	KETOCONAZOLE	CHEMBL295698		NCI	17518356
ABCG2	9429	CYCLOSPORINE	CHEMBL160	inhibitor	GuideToPharmacologyInteractions, NCI	16805961, 17031644
ABCG2	9429	ALVOCIDIB	CHEMBL428690		NCI	11205902
ABCG2	9429	SIROLIMUS	CHEMBL413		NCI	17031644
ABCG2	9429	MITOXANTRONE	CHEMBL58		TEND
ABCG2	9429	ITRACONAZOLE	CHEMBL22587		NCI	17518356
ABCG2	9429	NITROFURANTOIN	CHEMBL572		NCI	17093006
ABCG2	9429	VORICONAZOLE	CHEMBL638		NCI	17518356
ABCG2	9429	DIFLOMOTECAN	CHEMBL306280		PharmGKB
ABCG2	9429	ERLOTINIB	CHEMBL553		PharmGKB
ABCG2	9429	PRAVASTATIN	CHEMBL1144		NCI	17622941
ABCG2	9429	GONADOTROPIN, CHORIONIC	CHEMBL1201509		NCI	17823853
ABCG2	9429	IMATINIB	CHEMBL941		NCI	15805252
ABCG2	9429	FOLIC ACID	CHEMBL1622		NCI	15047700
ABCG2	9429	IMATINIB MESYLATE	CHEMBL1642		NCI	15805252

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
ABCG2	rs2231142	GT + TT	rosuvastatin	efficacy	no	ABCG2 421C>A did not significantly affect the lipid-lowering response of rosuvastatin.	Genotypes GT + TT are not associated with response to rosuvastatin as compared to genotype GG.	31857620	1451164800
ABCG2	rs2231142	GG + GT	atorvastatin	metabolism/PK	no	The AUC of atorvastatin in patients carrying ABCG2 c.421AA tended to be smaller compared with those in patients with c.421CC or c.421CA after its microdosing and therapeutic dosing. However, it did not reach statistical significance.	Genotypes GG + GT are not associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to genotype TT.	31594719	1451164971
ABCG2	rs2231142	GT + TT	rosuvastatin	metabolism/PK	yes	"The mean Css/D of RST and its metabolites were significantly higher in the subjects carrying the ABCG2 421A than in non-carriers of this allele. The effects of this allele remained significant after being adjusted by the baseline characteristics and false discovery rate (FDR) (Padj < 0.01, FDR < 0.05)."	Genotypes GT + TT are associated with increased concentrations of rosuvastatin as compared to genotype GG.	29950617	1451228555
ABCG2	rs2231142	T	rosuvastatin	efficacy	yes	as measured by achievement of their LDL cholesterol target (significance given for variants of either CYP3A5*1, 6986A>G, rs776746 and ABCG2; 421C>A, rs2231142).	Allele T is associated with increased response to rosuvastatin in people with Myocardial Infarction as compared to allele G.	20207952	1448107497
ABCG2	rs2231142	T	rosuvastatin	metabolism/PK	not stated	The authors compared PK parameters of rosuvastain between a Caucasian group (22) a Chinese (17), Filipino (19), Indian (16), Korean (23), Vietnamese(16), and Japanese (25) groups as well as a pooled "Asian" group. AUC(0-t) and C max were higher in subjects with the GT or TT genotypes compared with the GG genotype. The T allele may account for some but not all inter-ethnic group variability rosuvastatin PK. Within the Asian group the T allele appeared to have a greater effect in homozygotes although only five patients in the pooled Asian group were TT while there were no TT in the Caucasian population. Geometric mean Cmax pooled Asian group TT =44.56 versus GT =24.14 and GG =17.46 and Cmax Caucasian GT =11.97 versus GG =11.56. Geometric mean AUC (0-t) pooled Asian group TT =387.8, GT =222.4, GG =159.1 and AUC(0-t) Caucasian group GT =124.9 versus TT =111.4.	Allele T is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele G.	25630984	1444693893
ABCG2	rs2231142	G	tacrolimus	dosage	no	No significant difference in daily dose of tacrolimus was seen between genotypes of the rs2231142 SNP, at any point between 0 and 60 days after transplant. Please note alleles have been complemented to the plus chromosomal strand.	Allele G is not associated with dose of tacrolimus in children with hemopoietic stem cell transplant as compared to allele T.	20383212	1183959930
ABCG2	rs2231142	G	tacrolimus	dosage	no	No significant difference in clearance or blood concentration of tacrolimus was seen between the genotypes of the rs2231142 SNP, at any point between 0 and 60 days after transplant. Please note alleles have been complemented to the plus chromosomal strand.	Allele G is not associated with clearance of tacrolimus in children with hemopoietic stem cell transplant as compared to allele T.	20383212	1183960210
ABCG2	rs2231137	C	methotrexate	metabolism/PK	no	All patients received four cycles of high dose MTX (5000mg per square meter of body surface area). 1/10th of the dose was administered over 30 minutes (rapid infusion) and the rest was administered continuously over 24hrs. Leucovorin rescue was administered every 6hrs starting 48 hrs after initiation of MTX infusion.	Allele C is not associated with clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	24404132	1184175517
ABCG2	rs4148157	AA + AG	topotecan	metabolism/PK	yes	Absorption rate constant and circulating concentrations. Patients homozygous or heterozygous for G>A demonstrated Ka 2-fold higher than patients with GG genotype, and also a 2-fold higher maximal concentration. Patients stratified into one of three risk arms base on stage of metastasis, diagnosis, extent of resection, histologic subtype, and age at diagnosis (into low, intermediate, high). Each treatment arm had induction, consolidation, maintenance. During maintenance, patients got oral topotecan (0.8 mg/m2) for ten days and oral cyclophosphamide (30 mg/m2) for 21 days on a 28-day cycle for three cycles.	Genotypes AA + AG is associated with increased concentrations of topotecan in children with Brain Neoplasms as compared to genotype GG.	27052877	1447981305
ABCG2	rs13120400	CT + TT	deferasirox	metabolism/PK	yes	as measured by Volume of distribution (which was higher for CC vs CT/TT). This SNP was in complete LD with rs2231142	Genotypes CT + TT is associated with increased exposure to deferasirox in children with beta-Thalassemia as compared to genotype CC.	28346059	1448613522
ABCG2	rs2231137	C	methotrexate	efficacy	no	Please note: alleles have been complemented to the + chromosomal strand.	Allele C is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	28525903	1449003010
ABCG2	rs2231142	GT + TT	risperidone	metabolism/PK	yes	Alleles complemented to plus chromosomal strand.	Genotypes GT + TT is associated with decreased dose-adjusted trough concentrations of risperidone in children as compared to genotype GG.	28719598	1449005259
ABCG2	rs2231142	T	methotrexate	metabolism/PK	yes	The T allele is associated with longer half-life of methotrexate.	Allele T is associated with decreased metabolism of methotrexate in children with Osteosarcoma as compared to allele G.	27566582	1449188622
ABCG2	rs2231142	GT	rosuvastatin	metabolism/PK	no	Exposure was measured as Cmax and AUC 0-24.	Genotype GT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype GG.	28322941	1448612852
ABCG2	rs2231142	TT	sunitinib	metabolism/PK	no		Genotype TT is associated with increased exposure to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.	20348146	1448530349
ABCG2	rs2231142	G	lamotrigine	metabolism/PK	no		Allele G is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele T.	29791014	1449560381
ABCG2	rs2725252	AC + CC	imatinib	efficacy	yes	Individuals with the AC or CC genotype had a higher cumulative incidence of major molecular response (CI-MMR, estimated using Sokal score) after 18 months of treatment with a 400mg/day dose of imatinib, as compared to those with the AA genotype. No significant results were seen when considering patients taking a 600mg/day dose (n=107; p < 0.74). The authors note that they used the Benjamini and Hochberg method for multiple testing issues. Please also note that alleles have been complemented to the plus chromosomal strand.	Genotypes AC + CC is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype AA.	24123600	1184512528
ABCG2	rs2725252	C	imatinib	efficacy	yes	As part of a haplotype with rs12505410. Where response was defined as BCR-ABL/ABL standardized ratio (BCR-ABL^IS) of <=10% at 3 months, <=1% at 12 months and <=0.1% at 18 months. Patients were either taking 400mg/day or 600mg/day dose of imatinib. Those with the G-C haplotype (rs12505410-rs2725252) taking a 400mg/day dose had a significantly better response (under all definitions of response), as compared to those with any other haplotype (i.e. G-A, T-C, T-A). Results were NOT significant for those taking a 600mg/day dose (p=0.209, 0.316 and 0.209, respectively for the different response definitions). Please note that alleles for rs2725252 have been complemented to the plus chromosomal strand.	Allele C is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A.	24123600	1184513495
ABCG2	rs17731538	GG	methotrexate	efficacy	yes		Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to genotype AG.	18256692	747991835
ABCG2	rs13120400	CC	methotrexate	efficacy	yes		Genotype CC is associated with increased response to methotrexate in people with Psoriasis as compared to genotypes CT + TT.	18256692	748042563
ABCG2	rs2231142	GT	imatinib	"other","metabolism/PK"	yes	The association was with decreased clearance. Genotype alone was not associated, but genotype enhanced a more major association with body weight, albuminemia and plasma alpha1-acid glycoprotein. There were no TT in this small group(41 GG, 5 GT).	Genotype GT is associated with decreased metabolism of imatinib in people with Neoplasms as compared to genotype GG.	18981009	769169111
ABCG2	rs2231142	GG	gefitinib	efficacy	no		Genotype GG is not associated with increased response to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.	21332310	827784391
ABCG2	rs2622604	TT	gefitinib	efficacy	no		Genotype TT is not associated with increased response to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.	21332310	827784411
ABCG2	rs10011796	CT + TT	allopurinol	efficacy	no	Good response was defined as serum urate of < 6 mg/dl on a dose of allopurinol on less than 300 mg/day and poor response was defined as serum rate of greater than or equal to 6 mg/dl despite allopurinol of greater than 300 mg/d. The frequency of the CT and TT genotypes was not significantly different between the poor responder group (N=68) and the good responder group (N=120).	Genotypes CT + TT are not associated with response to allopurinol in people with Gout as compared to genotype CC.	26810134	1447982567
ABCG2	rs2725256	A	antiepileptics	efficacy	no	Epilepsy patients on antiepileptic drug (AED) treatment were divided into those with drug-responsive or drug-resistant epilepsy and genotypes and allele frequencies were compared. No significant association found with this variant.	Allele A is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele G.	21449672	827845728
ABCG2	rs3114020	T	antiepileptics	efficacy	no	Epilepsy patients on antiepileptic drug (AED) treatment were divided into those with drug-responsive or drug-resistant epilepsy and genotypes and allele frequencies were compared. No significant association found with this variant.	Allele T is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele C.	21449672	827845107
ABCG2	rs2231137	T	antiepileptics	efficacy	no	Epilepsy patients on antiepileptic drug (AED) treatment were divided into those with drug-responsive or drug-resistant epilepsy and genotypes and allele frequencies were compared. No significant association found with this variant.	Allele T is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele C.	21449672	827845129
ABCG2	rs17731799	G	antiepileptics	efficacy	no	Epilepsy patients on antiepileptic drug (AED) treatment were divided into those with drug-responsive or drug-resistant epilepsy and genotypes and allele frequencies were compared. No significant association found with this variant.	Allele G is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.	21449672	827845117
ABCG2	rs4148157	A	antiepileptics	efficacy	no	Epilepsy patients on antiepileptic drug (AED) treatment were divided into those with drug-responsive or drug-resistant epilepsy and genotypes and allele frequencies were compared. No significant association found with this variant.	Allele A is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele G.	21449672	827845755
ABCG2	rs2622628	C	antiepileptics	efficacy	no	Epilepsy patients on antiepileptic drug (AED) treatment were divided into those with drug-responsive or drug-resistant epilepsy and genotypes and allele frequencies were compared. No significant association found with this variant.	Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele A.	21449672	827845737
ABCG2	rs2231148	A	antiepileptics	efficacy	no	Please note, this variant was reported as A>T and the ABCG2 gene is on the minus chromosomal strand, therefore these alleles have been complemented for the plus strand. Epilepsy patients on antiepileptic drug (AED) treatment were divided into those with drug-responsive or drug-resistant epilepsy and genotypes and allele frequencies were compared. No significant association found with this variant.	Allele A is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.	21449672	827845746
ABCG2	rs2231142	T	antiepileptics	efficacy	no	Please note, alleles have been complemented for the plus strand. Epilepsy patients on antiepileptic drug (AED) treatment were divided into those with drug-responsive or drug-resistant epilepsy and genotypes and allele frequencies were compared. No significant association found with this variant.	Allele T is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele G.	21449672	827845705
ABCG2	rs17731538	G	antiepileptics	efficacy	no	Alleles have been complemented for the plus strand. Epilepsy patients on antiepileptic drug (AED) treatment were divided into those with drug-responsive or drug-resistant epilepsy and genotypes and allele frequencies were compared. No significant association found with this variant.	Allele G is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele A.	21449672	827845684
ABCG2	rs45499402	C	allopurinol	efficacy	yes	Response to allopurinol was determined by whether serum uric acid concentrations decreased following allopurinol treatment. This SNP is in perfect LD with rs2231142.	Allele C is associated with decreased response to allopurinol.	30924126	1450375534
ABCG2	rs2622604	T	methotrexate	metabolism/PK	no		Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	29791011	1450045145
ABCG2	rs3114018	C	methotrexate	metabolism/PK	no		Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	29791011	1450045139
ABCG2	rs2725252	C	imatinib	efficacy	yes	As part of a haplotype with rs12505410: those with the G-C haplotype (rs12505410-rs2725252) had a significantly higher cumulative incidence major molecular response (CI-MMR) as compared to those with any other haplotype (i.e. G-A, T-C, T-A). This study was done in an exploratory cohort (n=105) and a validation cohort (n=239); within the validation cohort, patients were either taking a 400mg/day dose of imatinib (n=132) or a 600mg/day dose (n=107). Results were NOT significant for those taking a 600mg/day dose. Please note that alleles have been complemented to the plus chromosomal strand.	Allele C is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A.	24123600	1184513472
ABCG2	rs3109823	C	antiepileptics	efficacy	no	Epilepsy patients on antiepileptic drug (AED) treatment were divided into those with drug-responsive or drug-resistant epilepsy and genotypes and allele frequencies were compared. No significant association found with this variant.	Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.	21449672	827845123
ABCG2	rs2231142	GG	fluorouracil	efficacy	no	Patients were taking either IFL (irinotecan + fluorouracil + leucovorin; n=114), FOLFOX (fluorouracil + oxaliplatin + leucovorin; n=299) or IROX (irinotecan + oxaliplatin; n=107). No significant association was seen between this variant and confirmed response rate, overall survival or time to progression in any of the treatment groups OR all treatment groups considered together. Significance level was set at 0.01.	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT.	20530282	1448522360
ABCG2	rs3219191	del	antiepileptics	efficacy	no	reported as rs3219191 I > D. Epilepsy patients on antiepileptic drug (AED) treatment were divided into those with drug-responsive or drug-resistant epilepsy and genotypes and allele frequencies were compared. No significant association found with this variant.	Allele del is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele TGAG.	21449672	827845112
ABCG2	rs2231142	GT	acetaminophen	metabolism/PK	no	There were no TT homozygotes and only 7 heterozygotes.	Genotype GT is not associated with clearance of acetaminophen as compared to genotype GG.	21241071	981477680
ABCG2	rs2231137	C	talinolol	metabolism/PK	no	This was a twin study of monozygotic and dizygotic twins.	Allele C is not associated with clearance of talinolol in healthy individuals as compared to allele T.	27825374	1448612429
ABCG2	rs2231142	GT + TT	rosuvastatin	metabolism/PK	yes	This variant affected rosuvastatin concentration significantly and potentially affect serum levels of pro-inflammatory and pro-angiogenic markers.	Genotypes GT + TT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype GG.	32361904	1451141440
ABCG2	rs2622628	AA	lamotrigine	metabolism/PK	no	Alleles given as T and G. The concentration was measured as lamotrigine trough concentration / dose normalized by body weight. Included patients had been on lamotrigine monotherapy for at least a month with complete medical records, had normal renal and hepatic functions, and had therapeutic drug monitoring with good compliance.	Genotype AA is not associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype CC.	26213157	1448098944
ABCG2	rs3114020	CC + CT	lamotrigine	metabolism/PK	yes	The concentration was measured as lamotrigine trough concentration / dose normalized by body weight. Included patients had been on lamotrigine monotherapy for at least a month with complete medical records, had normal renal and hepatic functions, and had therapeutic drug monitoring with good compliance.	Genotypes CC + CT are associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype TT.	26213157	1448098912
ABCG2	rs2231142	GT + TT	lamotrigine	metabolism/PK	yes	Alleles given as A and C. The concentration was measured as lamotrigine trough concentration / dose normalized by body weight. Included patients had been on lamotrigine monotherapy for at least a month with complete medical records, had normal renal and hepatic functions, and had therapeutic drug monitoring with good compliance.	Genotypes GT + TT are associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype GG.	26213157	1448098923
ABCG2	rs13120400	CC + CT	imatinib	efficacy	yes	Individuals with the CC or CT genotype had a higher cumulative incidence of major molecular response (CI-MMR, estimated using Sokal score) after 18 months of treatment with a 400mg/day dose of imatinib, as compared to those with the TT genotype. No significant results were seen when considering patients taking a 600mg/day dose (n=107; p=0.74). The authors note that they used the Benjamini and Hochberg method for multiple testing issues.	Genotypes CC + CT is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.	24123600	1184512524
ABCG2	rs72552713	AG	sulfasalazine	metabolism/PK	not stated	A single individual was compound heterozygous at rs72552713 (CT) and rs2231142 (GT) in BCRP as compared to other individuals who were heterozygous only at rs2231142 (GT). The individual had a higher AUC(0,48 h) as compared to other other individuals who were only heterozygous at rs2231142 (GT) (779 vs.292 ± 97 µgml–1h, respectively) as well as a higher Cmax (50.3 vs.24.0±9.3 µgml–1, respectively), and a lower apparent oral clearance (2.44 vs. 7.3 ±2.2 l h–1, respectively). Please note: alleles have been complemented to the + chromosomal strand.	Genotype AG is associated with decreased metabolism of sulfasalazine in healthy individuals.	25872459	1444843306
ABCG2	rs2231142	TT	apixaban	metabolism/PK	yes	GG genotype has higher concentration/dose ratio of apixaban.	Genotype TT is associated with increased concentrations of apixaban in people with Atrial Fibrillation as compared to genotype GG.	28678049	1448635726
ABCG2	rs1481012	AG + GG	rosuvastatin	efficacy	yes	The minor allele of this SNP is associated with increased fractional LDL-C reduction on rosuvastatin.	Genotypes AG + GG are associated with increased response to rosuvastatin as compared to genotype AA.	22331829	1447951990
ABCG2	rs2199939	CT + TT	rosuvastatin	efficacy	yes	The minor allele of this SNP is associated with increased LDL-C reduction on rosuvastatin. The mean per allele effect of rs2199936 was -5.2 mg/dL, corresponding to observed median LDL-C reductions of -53, -59, and -64 mg/dL for individuals with 0, 1, or 2 copies of the minor allele, respectively.	Genotypes CT + TT are associated with increased response to rosuvastatin as compared to genotype CC.	22331829	1447951958
ABCG2	rs2231142	GG	gefitinib	metabolism/PK	no	No significant difference in median area under the concentration-time curve from 0 to 24 hours (AUC0-24; p=0.323) or trough plasma concentration (C0; p=0.429) was seen between the two genotype groups. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype GG are not associated with concentrations of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.	25554506	1447948394
ABCG2	rs76979899	T	allopurinol	efficacy	no	Response to allopurinol was determined by whether serum uric acid concentrations decreased following allopurinol treatment.	Allele T is associated with decreased response to allopurinol as compared to allele C.	30924126	1450375658
ABCG2	rs2231142	GG	deferasirox	metabolism/PK	no	The genotype was not associated with area under the concentration curve (AUC) above the effectiveness cutoff of 360 micrograms/mL/h as compared in univariate analysis.	Genotype GG is not associated with concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes GT + TT.	27193993	1448101311
ABCG2	rs13120400	CC	deferasirox	metabolism/PK	yes	The CC genotype was associated with area under the concentration curve (AUC) above the effectiveness cutoff of 360 micrograms/mL/h as compared to the CT and TT genotypes in multivariate analysis.	Genotype CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.	27193993	1448101303
ABCG2	rs13120400	CC	deferasirox	metabolism/PK	yes	authors state this genotype is "positive predictive factor of AUC drug concentrations above 360 µg/ml/h, thus deferasirox effectiveness."	Genotype CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.	27043265	1447984241
ABCG2	rs2231142	G	hmg coa reductase inhibitors	efficacy	yes	as part of a three SNP genetic risk score with rs10455872 in LPA and rs2075650 in APOE. Associated allele not explicitly stated but methods reference Tomlinson et al. so used the associated allele from there [PMID:20130569].	Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to allele T.	27045730	1447986178
ABCG2	rs2231142	TT	lamotrigine	metabolism/PK	yes	Lamotrigine concentrations were measured as steady state in plasma in the early morning before breakfast after at least one month of continuous treatment with lamotrigine monotherapy. Alleles given as A and C.	Genotype TT is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotypes GG + GT.	27610747	1448263482
ABCG2	rs2231142	G	lamotrigine	efficacy	no	Alleles given as A and C. Efficacy was determined by monitoring the frequency of patients' epileptic seizures within one year. Each patient was evaluated at 4 weeks after treatment initiation and then at 3-month intervals thereafter. The difference in seizure frequency was based on the difference between the 3-month retrospective baseline frequency and the seizure frequency at 12-month visit, which was reported for the last 3 months prior to the last visit. Good efficacy was defined as seizure-free or a 50% or greater reduction in seizure frequency within a 1-year follow-up period.	Allele G is not associated with response to lamotrigine in people with Epilepsy as compared to allele T.	27610747	1448263541
ABCG2	rs2231137	CT	sorafenib	metabolism/PK	yes	measured by concentration/(dose/body weight) ratio. (alleles complemented to plus strand). No TT homozygotes were observed.	Genotype CT is associated with concentrations of sorafenib in people with Carcinoma, Hepatocellular as compared to genotype CC.	28289864	1448635296
ABCG2	rs2231142	TT	felodipine	metabolism/PK	yes		Genotype TT is associated with increased exposure to felodipine in healthy individuals as compared to genotypes GG + GT.	28244604	1448603074
ABCG2	rs2231142	T	selumetinib	metabolism/PK	no	Not associated with normalized dose when allele was assessed within ethnic groups (Asian, White, Black) and when all ethnic groups were pooled together.	Allele T is not associated with dose of selumetinib in healthy individuals as compared to allele G.	28283692	1448613498
ABCG2	rs2231142	GT	sorafenib	metabolism/PK	yes	measured by concentration/(dose/body weight) ratio. (alleles complemented to plus strand). No TT homozygotes were observed.	Genotype GT is associated with concentrations of sorafenib in people with Carcinoma, Hepatocellular as compared to genotype GG.	28289864	1448635307
ABCG2	rs2231142	G	talinolol	metabolism/PK	no	This was a twin study of monozygotic and dizygotic twins.	Allele G is not associated with clearance of talinolol in healthy individuals as compared to allele T.	27825374	1448612434
ABCG2	rs2231142	TT	n-desethyl sunitinib	"toxicity","metabolism/PK"	no	in a single case study. Authors state "Therefore, we speculated that the extremely high plasma concentrations of sunitinib and SU12662 caused by the ABCG2 421 AA genotype might have resulted in severe toxicities to the patient."	Genotype TT is associated with increased concentrations of n-desethyl sunitinib and sunitinib in women with Carcinoma, Renal Cell.	25515134	1448431572
ABCG2	rs2622604	C	sunitinib	metabolism/PK	no	as measured by C/D Ratio or total Sunitinib Dose-Adjusted Concentration.	Allele C is not associated with concentrations of sunitinib in people with Carcinoma, Renal Cell as compared to allele T.	25701374	1448530735
ABCG2	rs2231137	T	sunitinib	metabolism/PK	no	as measured by C/D Ratio or total Sunitinib Dose-Adjusted Concentration.	Allele T is not associated with concentrations of sunitinib in people with Carcinoma, Renal Cell as compared to allele C.	25701374	1448530729
ABCG2	rs2231142	T	sunitinib	metabolism/PK	no	as measured by C/D Ratio or total Sunitinib Dose-Adjusted Concentration.	Allele T is not associated with concentrations of sunitinib in people with Carcinoma, Renal Cell as compared to allele G.	25701374	1448530723
ABCG2	rs2231142	TT	dolutegravir	metabolism/PK	yes	mean peak plasma concentration	Genotype TT is associated with increased concentrations of dolutegravir in people with HIV Infections as compared to genotypes GG + GT.	28858994	1448995097
ABCG2	rs2231142	GT + TT	clozapine	metabolism/PK	yes	Alleles complemented to plus chromosomal strand.	Genotypes GT + TT is associated with increased dose-adjusted trough concentrations of clozapine in people with Schizophrenia as compared to genotype GG.	27932669	1449147375
ABCG2	rs2231142	GG + GT	apixaban	metabolism/PK	not stated		Genotypes GG + GT is associated with increased clearance of apixaban in people with Atrial Fibrillation as compared to genotype TT.	29457840	1449188612
ABCG2	rs2231142	GT + TT	iguratimod	efficacy	yes	Alleles complemented to plus strand.	Genotypes GT + TT is associated with increased clinical benefit to iguratimod in people with Arthritis, Rheumatoid as compared to genotype GG.	29517409	1449270444
ABCG2	rs2231142	T	allopurinol	dosage	yes	ABCG2 genotype and diuretic use explained 53% of the variability in prediction error.	Allele T is associated with increased dose of allopurinol in people with Gout as compared to allele G.	29341237	1449165252
ABCG2	rs13120400	CC	voriconazole	metabolism/PK	yes	TT/TC genotype group (n = 224): median Ctrough of 1.77 µg/ml (IQR: 0.74–3.02 µg/ml); CC genotype (n = 8): median Ctrough of 5.30 µg/ml (IQR: 1.96–7.74 µg/ml).	Genotype CC is associated with increased trough concentration of voriconazole in children as compared to genotypes CT + TT.	29914286	1449593570
ABCG2	rs2231142	TT	Opioid anesthetics	efficacy	yes	The TT genotype was significantly associated with a shorter recovery time from general anesthesia compared to the GG and GT genotypes.	Genotype TT is associated with increased response to Opioid anesthetics, Other general anesthetics or volatile anesthetics as compared to genotypes GG + GT.	30136624	1449717930
ABCG2	rs2231142	T	axitinib	metabolism/PK	yes	The authors develop a prediction model and calculated area under the concentration curve (AUC) using 6 SNPs (rs17868323, rs3832043, rs2231142, rs2032582, rs1045642, rs35305980) was compared with actual AUC in 16 patients prospectively which significantly correlated with the objective response rate (P = 0.0002), hand-foot syndrome, P = 0.0055 and hypothyroidism, P = 0.0381, and correlated with actual AUC (P < 0.0001) - the validation study, calculated AUC prior to axitinib treatment precisely predicted actual AUC after axitinib treatment (P = 0.0066).	Allele T is associated with concentrations of axitinib in people with Carcinoma, Renal Cell as compared to allele G.	29682213	1449310596
ABCG2	rs10011796	T	allopurinol	dosage	no		Allele T is not associated with dose of allopurinol in people with Gout as compared to allele C.	29341237	1449166167
ABCG2	rs2231137	CC	methotrexate	toxicity	no	Discontinuation due to adverse effects. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype CC is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype CT.	27217051	1449164825
ABCG2	rs2231142	G	methotrexate	toxicity	no	Discontinuation due to adverse effects. Please note that alleles have been complemented to the plus chromosomal strand.	Allele G is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	27217051	1449164833
ABCG2	rs12505410	G	imatinib	efficacy	yes	As part of a haplotype with rs2725252: those with the G-C haplotype (rs12505410-rs2725252) had a significantly higher cumulative incidence major molecular response (CI-MMR) as compared to those with any other haplotype (i.e. G-A, T-C, T-A). This study was done in an exploratory cohort (n=105) and a validation cohort (n=239); within the validation cohort, patients were either taking a 400mg/day dose of imatinib (n=132) or a 600mg/day dose (n=107). Results were NOT significant for those taking a 600mg/day dose. Please note that alleles for rs2725252 have been complemented to the plus chromosomal strand.	Allele G is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele T.	24123600	1184512509
ABCG2	rs12505410	GG + GT	imatinib	efficacy	yes	Individuals with the GG or GT genotype had a higher cumulative incidence of major molecular response (CI-MMR, estimated using Sokal score) after 18 months of treatment with a 400mg/day dose of imatinib, as compared to those with the TT genotype. No significant results were seen when considering patients taking a 600mg/day dose (n=107; p=0.32), though significant results were seen when considering all patients (n=239; p=0.045). The authors note that they used the Benjamini and Hochberg method for multiple testing issues.	Genotypes GG + GT is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.	24123600	1184512515
ABCG2	rs12505410	G	imatinib	efficacy	yes	As part of a haplotype with rs2725252. Where response was defined as BCR-ABL/ABL standardized ratio (BCR-ABL^IS) of <=10% at 3 months, <=1% at 12 months and <=0.1% at 18 months. Patients were either taking 400mg/day or 600mg/day dose of imatinib. Those with the G-C haplotype (rs12505410-rs2725252) taking a 400mg/day dose had a significantly better response (under all definitions of response), as compared to those with any other haplotype (i.e. G-A, T-C, T-A). Results were NOT significant for those taking a 600mg/day dose (p=0.209, 0.316 and 0.209, respectively for the different response definitions). Please note that alleles for rs2725252 have been complemented to the plus chromosomal strand.	Allele G is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele T.	24123600	1184513485
ABCG2	rs12505410	GG	methotrexate	metabolism/PK	yes	The GG genotype was associated with a 12% increase in methotrexate clearance under a recessive model. Please note that alleles have been complemented to the positive strand. This allele was correlated with rs13120400 (r2=0.69).	Genotype GG is associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotypes GT + TT.	29791011	1450045157
ABCG2	rs2231142	T	ceftriaxone	metabolism/PK	no	Please note that alleles have been complemented to the positive strand. No significant association was found between this variant and concentrations of ceftriaxone in the plasma or cerebrospinal fluid (CSF) of patients. There was also no significant association between this variant and ceftriaxone CSF to plasma ratios.	Allele T is not associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to allele G.	29873816	1450044766
ABCG2	rs13120400	TT	ceftriaxone	metabolism/PK	yes	Patients with the TT genotype had a significantly increased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone compared to CC and TT patients. However, there was no significant association between this variant and concentrations of ceftriaxone in the plasma or CSF of patients.	Genotype TT is associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to genotypes CC + CT.	29873816	1450044772
ABCG2	rs2231142	G	imatinib	dosage	no	No significant association between genotype and chance of requiring an imatinib dose reduction. Please note that alleles have been complemented to the positive strand.	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele T.	30713339	1450933245
ABCG2	rs4148157	A	allopurinol	efficacy	no	Response to allopurinol was determined by whether serum uric acid concentrations decreased following allopurinol treatment.	Allele A is associated with decreased response to allopurinol as compared to allele G.	30924126	1450375599
ABCG2	rs2231142	T	allopurinol	efficacy	yes	Response to allopurinol was determined by whether serum uric acid concentrations decreased following allopurinol treatment. This SNP is in perfect LD with rs45499402.	Allele T is associated with decreased response to allopurinol as compared to allele G.	30924126	1450375524
ABCG2	rs10011796	T	allopurinol	efficacy	no	Response to allopurinol was determined by whether serum uric acid concentrations decreased following allopurinol treatment.	Allele T is associated with decreased response to allopurinol as compared to allele C.	30924126	1450375616
ABCG2	rs4148155	G	allopurinol	efficacy	no	Response to allopurinol was determined by whether serum uric acid concentrations decreased following allopurinol treatment.	Allele G is associated with decreased response to allopurinol as compared to allele A.	30924126	1450375583
ABCG2	rs2725252	C	methotrexate	metabolism/PK	no	Please note that alleles have been complemented to the positive strand.	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	29791011	1450045133
ABCG2	rs13120400	CC	methotrexate	metabolism/PK	yes	The CC genotype was associated with a 16% increase in methotrexate clearance under a recessive model. Please note that alleles have been complemented to the positive strand. This allele was correlated with both rs13137622 (r2=0.65) and rs12505410 (r2=0.69).	Genotype CC is associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotypes CT + TT.	29791011	1450045121
ABCG2	rs17731538	A	methotrexate	metabolism/PK	no	Please note that alleles have been complemented to the positive strand.	Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele G.	29791011	1450045163
ABCG2	rs1564481	T	methotrexate	metabolism/PK	no	Please note that alleles have been complemented to the positive strand.	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	29791011	1450045115
ABCG2	rs2622621	G	methotrexate	metabolism/PK	no	Based on the MAF given in the paper, it is assumed that these alleles are reported as being on the positive strand. Therefore, they have not been complemented in this annotation.	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	29791011	1450045151
ABCG2	rs13137622	GT + TT	methotrexate	metabolism/PK	yes	A 6% increase in methotrexate clearance was associated with each copy of the T allele present under an additive model. Please note that alleles have been complemented to the positive strand. This allele was correlated with rs13120400 (r2=0.65)	Genotypes GT + TT are associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotype GG.	29791011	1450045127
ABCG2	rs6857600	T	methotrexate	metabolism/PK	no		Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	29791011	1450045169
ABCG2	rs2231142	T	letermovir	metabolism/PK	no	No significant association between this variant and letermovir AUC.	Allele T is not associated with exposure to letermovir as compared to allele G.	31022310	1451105117
ABCG2	rs2231142	T	pitavastatin	metabolism/PK	no	Please note that alleles have been complemented to the positive strand.	Allele T is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.	23007012	1450814797
ABCG2	rs2231137	CT + TT	imatinib	dosage	yes	Patients carrying the T allele were significantly more likely to require a dose reduction compared to patients with the CC genotype. Please note that alleles have been complemented to the positive strand.	Genotypes CT + TT are associated with decreased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.	30713339	1450933220
ABCG2	rs2231142	T	selumetinib	metabolism/PK	no	Not associated with AUC, AUC0-12 when allele was assessed within ethnic groups (Asian, White, Black) and when all ethnic groups were pooled together. Only P-values for AUC presented here.	Allele T is not associated with metabolism of selumetinib in healthy individuals as compared to allele G.	28283692	1448613426
ABCG2	rs2231137	C	lamotrigine	efficacy	no	Alleles given as A and G. Efficacy was determined by monitoring the frequency of patients' epileptic seizures within one year. Each patient was evaluated at 4 weeks after treatment initiation and then at 3-month intervals thereafter. The difference in seizure frequency was based on the difference between the 3-month retrospective baseline frequency and the seizure frequency at 12-month visit, which was reported for the last 3 months prior to the last visit. Good efficacy was defined as seizure-free or a 50% or greater reduction in seizure frequency within a 1-year follow-up period.	Allele C is not associated with response to lamotrigine in people with Epilepsy as compared to allele T.	27610747	1448263533
ABCG2	rs2231137	CC	lamotrigine	metabolism/PK	no	Lamotrigine concentrations were measured as steady state in plasma in the early morning before breakfast after at least one month of continuous treatment with lamotrigine monotherapy. Alleles given as A and G.	Genotype CC is not associated with concentrations of lamotrigine in people with Epilepsy as compared to genotype TT.	27610747	1448263476
ABCG2	rs2231137	TT	granisetron	efficacy	no	Patients with cancer, treated with cisplatin who had been treated with granisetron and palonsetron. Nausea and vomiting episodes were recorded for the first 120 h post cisplatin. With regard to vomiting events, presence/absence of symptoms and the time of onset were described. Nausea severity was categorized using a 4-point Likert scale (0 = no nausea, 1 = mild nausea, 2 = moderate nausea and 3 = severe nausea) according to the subjective assessment of each patient.	Genotype TT is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes CC + CT.	29177570	1449170244
ABCG2	rs2231142	TT	sulfasalazine	metabolism/PK	yes	A single oral dose was given and pharmacokinetic parameters were measured at different times points. Parameters AUC0-48, Cmax and CLtotal/F were all significantly different in individuals with the GT genotype compared to GG, and in individuals with the TT genotype compared to GG and compared to GT. Mean plasma concentrations of Sulfasalazine at all time points were significantly higher in TT subjects compared to GG (0-48 hours, except 0.5 hours).	Genotype TT is associated with decreased clearance of sulfasalazine in healthy individuals as compared to genotypes GG + GT.	18167504	981501360
ABCG2	rs2231137	CC + CT	methotrexate	metabolism/PK	no	There is no association between selected SNPs and methotrexate plasma level at 48 h between the first dose of methotrexate infusion. med. MTX concentration: CC +TC (0.45 (0.09–41.63)) vs. TT(0.46 (0.15–10.29)). Please note: alleles have been complemented to the + chromosomal strand.	Genotypes CC + CT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	28525903	1449003399
ABCG2	rs2231142	GG	antineoplastic agents	efficacy	yes	Patients with the GG genotype receiving a FOLFOX/XELOX regimen (respectively: fluorouracil, leucovorin, oxaliplatin; capecitabine, oxaliplatin) had a decreased response rate, as compared to those with the GT or TT genotype. No significant difference in response rate was seen in patients receiving a FOLFIRI regimen (fluorouracil, leucovorin, irinotecan). No significant differences in progression-free survival were seen for either regimen. Please note alleles have been complemented to the plus chromosomal strand.	Genotype GG is associated with decreased response to antineoplastic agents in people with Colorectal Neoplasms as compared to genotypes GT + TT.	24338217	1184747603
ABCG2	rs2231142	T	sulfasalazine	other	no	No significant difference in likelihood of cessation of sulphasalazine treatment due to adverse effects was seen between those who carried the T allele and those who did not. Most common adverse events were nausea/vomiting and fatigue/lethargy; please refer to paper for full list. Note that alleles have been complemented to the plus chromosomal strand.	Allele T is not associated with discontinuation of sulfasalazine in people with Arthritis, Rheumatoid as compared to allele G.	24394199	1184747642
ABCG2	rs2231142	GT + TT	sulfasalazine	efficacy	yes	After adjusting for age, baseline DAS28, smoking status and shared epitope positivity, those who carried one or more T allele were more likely to achieve remission after 12 months of treatment. Remission defined as an SDAI of <3.3. Please note that alleles have been complemented to the positive chromosomal strand.	Genotypes GT + TT are associated with increased response to sulfasalazine in people with Arthritis, Rheumatoid as compared to genotype GG.	24394199	1184747648
ABCG2	rs2231142	TT	sulfasalazine	metabolism/PK	not stated	The mean AUC(0,48 h) was 3-fold higher and Cmax was 2.5-fold higher in individuals with the TT genotype as compared to individuals with the GG genotype. The apparent oral clearance (dose/ AUC(0,48 h)) was 3-fold lower in individuals with the TT genotype as compared to individuals with the GG genotype. The authors reported no differences in sulfasalazine PK between the GG genotype and GT genotype, however a single individual was compound heterozygous at rs72552713 (CT) and rs2231142 (GT) in and altered PK as compared to other individuals who were heterozygous only at rs2231142 (GT). Please note: alleles have been complemented to the + chromosomal strand.	Genotype TT is associated with decreased clearance of sulfasalazine in healthy individuals as compared to genotypes GG + GT.	25872459	1444843284
ABCG2	rs2231142	T	allopurinol	efficacy	yes	The authors designated "response to allopurinol" as a reduction of serum uric acid levels to below 6 mg/dL. Mean age was 68 years, 75% were male. The elevated mean baseline SUA before treatment was 8.9 mg/dL. No other SNPs reached genome wide significance.	Allele T is associated with decreased response to allopurinol in people with Gout as compared to allele G.	25676789	1444703466
ABCG2	rs2231142	TT	methotrexate	metabolism/PK	no	TT vs GG and TG vs GG were not statistically significant.	Genotype TT is not associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	25303299	1296598942
ABCG2	rs2231142	TT	sunitinib	efficacy	no	The genotype was not associated with progression free survival, or overall survival, or clinical benefit. Clinical benefit was defined as either partial response or stable disease. Please note, alleles have been complemented to the + chromosomal strand.	Genotype TT is not associated with response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.	26244574	1446735619
ABCG2	rs2231142	GT + TT	atorvastatin	efficacy	no	The authors tested whether differences in the following biomarkers that corresponded to genotype (dominant model): triglycerides, HDL-cholsterol, LDL-cholesterol, and total cholesterol.	Genotypes GT + TT are not associated with response to atorvastatin in people with Hypercholesterolemia as compared to genotype GG.	28833323	1449001968
ABCG2	rs2231142	GT + TT	sunitinib	metabolism/PK	yes	The dose-normalized area under the plasma concentration-time curve from 0 to 24 hours (AUC) for the composite of sunitinib + SU12662 (its active metabolite) was highest for those with the TT genotype, followed by those with the GT genotype then those with the GG genotype (TT>GT>GG). This SNP was identified as a statistically significant variability factor for composite exposure. Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes GT + TT is associated with increased exposure to sunitinib in people with Neoplasms as compared to genotype GG.	25344452	1446903052
ABCG2	rs2231142	GT + TT	allopurinol	efficacy	yes	Good response was defined as serum urate of < 6 mg/dl on a dose of allopurinol on less than 300 mg/day and poor response was defined as serum urate of greater than or equal to 6 mg/dl despite allopurinol of greater than 300 mg/d. The frequency of the GT and TT genotypes was higher in the poor responder group (N=68) than in the good responder group (N=120). This association remained significant even after adjusting for gender, BMI, ethnicity, estimated glomerular filtration rate, diuretic use, and serum urate concentration at baseline.	Genotypes GT + TT are associated with decreased response to allopurinol in people with Gout as compared to genotype GG.	26810134	1447982552
ABCG2	rs2231142	GG	gefitinib	metabolism/PK	no	No significant difference in area under the plasma concentration-time curve (AUC) or maximum plasma concentration (Cmax) or trough concentrations (C0) was seen between the genotypes. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype GG is not associated with metabolism of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.	26898617	1447948535
ABCG2	rs2231142	TT	granisetron	efficacy	no	There was no significant association between this variant and proportion of patients showing a "complete response" to antiemetic treatment during the first 120 hours after cisplatin-based chemotherapy initiation. Complete response defined as no vomiting episodes or no use of rescue medication. Patients were either receiving granisetron (n=79) or palonosetron (n=77), both in combination with dexamethasone and aprepitant. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype TT is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes GG + GT.	27241063	1448427759
ABCG2	rs2231142	T	imatinib	efficacy	yes	Direction of relationship not explicitly stated. Assumed minor allele as T and having lower odds ratio of response. Alleles complemented to plus strand as gene is on minus chromosomal strand.	Allele T is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.	27991849	1448594125
ABCG2	rs2231142	GT + TT	tenofovir	metabolism/PK	yes	Patients with the GT or TT genotype had a 1.51-fold increase in tenofovir area under the concentration-time curve (AUC) as compared to those with the GG genotype. Multivariable model controlling for age (per decade), body mass index (per 10 percent increase), African American race, ritonavir use, and whether eGFR is less than 70 ml/min per 1.73m2.	Genotypes GT + TT are associated with increased concentrations of tenofovir in women with HIV Infections as compared to genotype GG.	28462920	1448821487
ABCG2	rs2231142	TT	granisetron	efficacy	no	Patients with cancer, treated with cisplatin who had been treated with granisetron and palonsetron. Nausea and vomiting episodes were recorded for the first 120 h post cisplatin. With regard to vomiting events, presence/absence of symptoms and the time of onset were described. Nausea severity was categorized using a 4-point Likert scale (0 = no nausea, 1 = mild nausea, 2 = moderate nausea and 3 = severe nausea) according to the subjective assessment of each patient.	Genotype TT is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes GG + GT.	29177570	1449170252
ABCG2	rs2231142	GT	sulfasalazine	dosage	no	Exposure was measured as Cmax and AUC 0-24.	Genotype GT is associated with increased exposure to sulfasalazine in healthy individuals as compared to genotype GG.	28322941	1448612847
ABCG2	rs2231142	T	lamotrigine	metabolism/PK	yes	In patients with the AA and AG genotype, steady-state measured and dose-adjusted lamotrigine trough concentration was higher in those administered lamotrigine as compared to the GG genotype and lower in those administered lamotrigine only as compared to the GG genotype.	Allele T is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to allele G.	29791014	1449560343
ABCG2	rs2231142	GT + TT	rosuvastatin	metabolism/PK	yes	The exposure to rosuvastatin increased by 44% in young subjects (p = 0.0021) with BCRP intermediate function (IF) and by 35% and 59% (p > 0.05 for both) in elderly subjects with BCRP IF and low function.The ABCG2 421C > A polymorphism was identified as a more important determinant than the SLCO1B1 521T > C polymorphism in both elderly and young subjects.	Genotypes GT + TT are associated with increased concentrations of rosuvastatin as compared to genotype GG.	31857620	1451124102